Showing results (871-880 of 1,009) with videos related to
Sort By:
Pageof 101
Journal of Opioid Management|December 25, 2012
Is opioid-induced hyperalgesia reversible? A study on active and former opioid addicts and drug naïve controlsRoi Treister, Elon Eisenberg, Eli Lawental, et al.Journal of Opioid Management|December 25, 2012
Risk factors for drug diversion in a pain clinic patient populationMary Jean Walker, Lynn R WebsterJournal of Opioid Management|May 28, 2013
Reported side effects, bother, satisfaction, and adherence in patients taking hydrocodone for non-cancer painKathryn P Anastassopoulos, Wing Chow, Crisanta I Tapia, et al.Journal of Opioid Management|June 18, 2013
Rationale and design of the Oxycodone Users Registry: a prospective, multicenter registry of patients with nonmalignant painMyoung Kim, Wing Chow, Carmela BensonJournal of Opioid Management|June 18, 2013
Gastrointestinal events after opioid treatment in nonmalignant pain: correlates of occurrence and impact on health-related quality of lifeKate L Lapane, Brian J Quilliam, Carmela Benson, et al.Journal of Opioid Management|June 18, 2013
Opioid prescribing knowledge and practices: provider survey following promulgation of guidelines-Utah, 2011Christina A Porucznik, Erin M Johnson, Robert T Rolfs, et al.Journal of Opioid Management|May 24, 2012
Do transdermal opioids affect the personal socioeconomic costs of healthcare access in an australian rural pain population? A comparison with oral opioidsJohn S Henshaw, Judi Walker, Dom GeraghtyJournal of Opioid Management|January 16, 2010
Postoperative analgesia after radical prostatectomy with high-dose intrathecal morphine and intravenous naloxone: a retrospective reviewAnnette Rebel, Paul Sloan, Michael AndrykowskiJournal of Opioid Management|September 21, 2018
Impact of rescheduling hydrocodone-combination products in an urban Texas county healthcare systemJohn W Shumway, Renzhong Ran, Jeff McClusky, et al.Journal of Opioid Management|September 21, 2018
Provider reasons for discontinuing long-term opioid therapy following aberrant urine drug tests differ based on the type of substance identifiedJessica J Wyse, Benjamin J Morasco, Steven K Dobscha, et al.Pageof 101